Literature DB >> 12358915

Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B-cell lymphoma.

Kevin W Song1, Peter Mollee, Bruce Patterson, William Brien, Michael Crump.   

Abstract

A 26-year-old woman, diagnosed with diffuse large B-cell lymphoma, was treated with CHOP (cyclophosphamide, hydroxydaunomycin, oncovin, prednisone), rituximab and radiotherapy. She developed transfusion-dependant anaemia, which persisted following chemotherapy. Bone marrow aspirate and biopsy were consistent with pure red cell aplasia and parvovirus infection. Serology was negative for previous or acute infection but parvovirus DNA was detected by polymerase chain reaction. Administration of intravenous immunoglobulin (1 g/kg) resulted in reticulocytosis and recovery of her haemoglobin. We hypothesize that rituximab caused depletion of her normal B cells, resulting in an inability to mount a primary immune response to parvovirus infection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12358915     DOI: 10.1046/j.1365-2141.2002.03778.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  9 in total

1.  Use of rituximab in three children with relapsed/refractory Burkitt lymphoma.

Authors:  Sinan Akbayram; Murat Doğan; Cihangir Akgün; Fatih Erbey; Hüseyin Caksen; Ahmet Faik Oner
Journal:  Target Oncol       Date:  2010-09-22       Impact factor: 4.493

Review 2.  Evidence for the use of intravenous immunoglobulins--a review of the literature.

Authors:  Shaye Kivity; Uriel Katz; Natalie Daniel; Udi Nussinovitch; Neophytos Papageorgiou; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

3.  Rituximab therapy for primary glomerulonephritis: Report on two cases.

Authors:  Fabrizio Fabrizi; Donata Cresseri; Giovanni B Fogazzi; Gabriella Moroni; Patrizia Passerini; Paul Martin; Piergiorgio Messa
Journal:  World J Clin Cases       Date:  2015-08-16       Impact factor: 1.337

4.  Rituximab used in three cases with relapsed non-Hodgkin's lymphoma.

Authors:  Murat Elli; Sema Yilmaz; Ramazan Aydin; Sadriye Murat; Meltem Ceyhan Bilgici; Ayhan Dagdemir
Journal:  Mol Clin Oncol       Date:  2013-03-05

Review 5.  Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis.

Authors:  Simone Lanini; Aoife C Molloy; Paul E Fine; Archibald G Prentice; Giuseppe Ippolito; Christopher C Kibbler
Journal:  BMC Med       Date:  2011-04-12       Impact factor: 8.775

6.  B cells as a therapeutic target in autoimmune disease.

Authors:  Jörg J Goronzy; Cornelia M Weyand
Journal:  Arthritis Res Ther       Date:  2003-03-19       Impact factor: 5.156

7.  Pembrolizumab-induced Pure Red Cell Aplasia Successfully Treated with Intravenous Immunoglobulin.

Authors:  Atsushi Isoda; Yuri Miyazawa; Kenichi Tahara; Masahiro Mihara; Akio Saito; Morio Matsumoto; Morio Sawamura
Journal:  Intern Med       Date:  2020-05-08       Impact factor: 1.271

8.  Persistent anemia in a patient with diffuse large B cell lymphoma: pure red cell aplasia associated with latent Epstein-Barr virus infection in bone marrow.

Authors:  Hwa Jung Sung; Seok Jin Kim; Ji Hye Lee; Goeun Lee; Kyung A Lee; Chul Won Choi; Byung Soo Kim; Jun Suk Kim
Journal:  J Korean Med Sci       Date:  2007-09       Impact factor: 2.153

Review 9.  Acquired pure red cell aplasia: updated review of treatment.

Authors:  Kenichi Sawada; Naohito Fujishima; Makoto Hirokawa
Journal:  Br J Haematol       Date:  2008-05-28       Impact factor: 6.998

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.